71 related articles for article (PubMed ID: 36275814)
21. Milder outcomes of SARS-CoV-2 genetically confirmed reinfections compared to primary infections with the delta variant: A retrospective case-control study.
Suljič A; Sočan M; Mrzel M; Lunar MM; Korva M; Štorman A; Prosenc K; Janežič S; Žohar-Čretnik T; Zupanič T; Poljak M; Avšič-Županc T
Front Med (Lausanne); 2022; 9():962653. PubMed ID: 36275814
[TBL] [Abstract][Full Text] [Related]
22. Role of previous infection with SARS-CoV-2 in protecting against omicron reinfections and severe complications of COVID-19 compared to pre-omicron variants: a systematic review.
Arabi M; Al-Najjar Y; Sharma O; Kamal I; Javed A; Gohil HS; Paul P; Al-Khalifa AM; Laws S; Zakaria D
BMC Infect Dis; 2023 Jun; 23(1):432. PubMed ID: 37365490
[TBL] [Abstract][Full Text] [Related]
23. Protection of hybrid immunity against SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant predominance in Mexico.
Montes-González JA; Zaragoza-Jiménez CA; Antonio-Villa NE; Fermín-Martínez CA; Ramírez-García D; Vargas-Vázquez A; Gutiérrez-Vargas RI; García-Rodríguez G; López-Gatell H; Valdés-Ferrer SI; Bello-Chavolla OY
Front Public Health; 2023; 11():1146059. PubMed ID: 37081954
[TBL] [Abstract][Full Text] [Related]
24. Frequency and risk of SARS-CoV-2 reinfections in Norway: a nation-wide study, February 2020 to January 2022.
Bøås H; Storm ML; Tapia G; Kristoffersen AB; Løvlie AL; Størdal K; Lyngstad TM; Bragstad K; Hungnes O; Veneti L
BMC Public Health; 2024 Jan; 24(1):181. PubMed ID: 38225588
[TBL] [Abstract][Full Text] [Related]
25. Risk of SARS-CoV-2 reinfections in children: a prospective national surveillance study between January, 2020, and July, 2021, in England.
Mensah AA; Campbell H; Stowe J; Seghezzo G; Simmons R; Lacy J; Bukasa A; O'Boyle S; Ramsay ME; Brown K; Ladhani SN
Lancet Child Adolesc Health; 2022 Jun; 6(6):384-392. PubMed ID: 35358491
[TBL] [Abstract][Full Text] [Related]
26. Incidence, Risk, and Severity of SARS-CoV-2 Reinfections in Children and Adolescents Between March 2020 and July 2022 in Serbia.
Medic S; Anastassopoulou C; Lozanov-Crvenkovic Z; Dragnic N; Petrovic V; Ristic M; Pustahija T; Tsakris A; Ioannidis JPA
JAMA Netw Open; 2023 Feb; 6(2):e2255779. PubMed ID: 36780157
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the Acceptance Rate of Covid-19 Vaccine and its Associated Factors: A Systematic Review and Meta-analysis.
Kazeminia M; Afshar ZM; Rajati M; Saeedi A; Rajati F
J Prev (2022); 2022 Aug; 43(4):421-467. PubMed ID: 35687259
[TBL] [Abstract][Full Text] [Related]
28. Clinical manifestations, treatment options, and comorbidities in COVID-19 relapse patients: A systematic review.
Koupaei M; Mohamadi MH; Yashmi I; Shahabi AH; Shabani AH; Heidary M; Khoshnood S
J Clin Lab Anal; 2022 May; 36(5):e24402. PubMed ID: 35396748
[TBL] [Abstract][Full Text] [Related]
29. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Naturally Acquired Immunity versus Vaccine-induced Immunity, Reinfections versus Breakthrough Infections: A Retrospective Cohort Study.
Gazit S; Shlezinger R; Perez G; Lotan R; Peretz A; Ben-Tov A; Herzel E; Alapi H; Cohen D; Muhsen K; Chodick G; Patalon T
Clin Infect Dis; 2022 Aug; 75(1):e545-e551. PubMed ID: 35380632
[TBL] [Abstract][Full Text] [Related]
30. Clinical and Virological Characteristics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) B.1.617.2 (Delta) Variant: A Prospective Cohort Study.
Park S; Lim SY; Kim JY; Park H; Lim JS; Bae S; Kim J; Jung J; Kim MJ; Chong YP; Choi SH; Lee SO; Kim YS; Park MS; Kim SH
Clin Infect Dis; 2022 Aug; 75(1):e27-e34. PubMed ID: 35362530
[TBL] [Abstract][Full Text] [Related]
31. SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity.
Pilz S; Theiler-Schwetz V; Trummer C; Krause R; Ioannidis JPA
Environ Res; 2022 Jun; 209():112911. PubMed ID: 35149106
[TBL] [Abstract][Full Text] [Related]
32. Increased transmissibility of SARS-CoV-2 lineage B.1.1.7 by age and viral load.
Lyngse FP; Mølbak K; Skov RL; Christiansen LE; Mortensen LH; Albertsen M; Møller CH; Krause TG; Rasmussen M; Michaelsen TY; Voldstedlund M; Fonager J; Steenhard N; ; Kirkeby CT
Nat Commun; 2021 Dec; 12(1):7251. PubMed ID: 34903718
[TBL] [Abstract][Full Text] [Related]
33. Duration of Severe Acute Respiratory Syndrome Coronavirus 2 Natural Immunity and Protection Against the Delta Variant: A Retrospective Cohort Study.
Kim P; Gordon SM; Sheehan MM; Rothberg MB
Clin Infect Dis; 2022 Aug; 75(1):e185-e190. PubMed ID: 34864907
[TBL] [Abstract][Full Text] [Related]
34. Protective immunity after recovery from SARS-CoV-2 infection.
Kojima N; Klausner JD
Lancet Infect Dis; 2022 Jan; 22(1):12-14. PubMed ID: 34762853
[No Abstract] [Full Text] [Related]
35. Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada.
Fisman DN; Tuite AR
CMAJ; 2021 Oct; 193(42):E1619-E1625. PubMed ID: 34610919
[TBL] [Abstract][Full Text] [Related]
36. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion.
Mlcochova P; Kemp SA; Dhar MS; Papa G; Meng B; Ferreira IATM; Datir R; Collier DA; Albecka A; Singh S; Pandey R; Brown J; Zhou J; Goonawardane N; Mishra S; Whittaker C; Mellan T; Marwal R; Datta M; Sengupta S; Ponnusamy K; Radhakrishnan VS; Abdullahi A; Charles O; Chattopadhyay P; Devi P; Caputo D; Peacock T; Wattal C; Goel N; Satwik A; Vaishya R; Agarwal M; ; ; ; Mavousian A; Lee JH; Bassi J; Silacci-Fegni C; Saliba C; Pinto D; Irie T; Yoshida I; Hamilton WL; Sato K; Bhatt S; Flaxman S; James LC; Corti D; Piccoli L; Barclay WS; Rakshit P; Agrawal A; Gupta RK
Nature; 2021 Nov; 599(7883):114-119. PubMed ID: 34488225
[TBL] [Abstract][Full Text] [Related]
37. Clinical and Virological Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta).
Ong SWX; Chiew CJ; Ang LW; Mak TM; Cui L; Toh MPHS; Lim YD; Lee PH; Lee TH; Chia PY; Maurer-Stroh S; Lin RTP; Leo YS; Lee VJ; Lye DC; Young BE
Clin Infect Dis; 2022 Aug; 75(1):e1128-e1136. PubMed ID: 34423834
[TBL] [Abstract][Full Text] [Related]
38. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.
Andreano E; Piccini G; Licastro D; Casalino L; Johnson NV; Paciello I; Dal Monego S; Pantano E; Manganaro N; Manenti A; Manna R; Casa E; Hyseni I; Benincasa L; Montomoli E; Amaro RE; McLellan JS; Rappuoli R
Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34417349
[TBL] [Abstract][Full Text] [Related]
39. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis.
Lopez-Leon S; Wegman-Ostrosky T; Perelman C; Sepulveda R; Rebolledo PA; Cuapio A; Villapol S
Sci Rep; 2021 Aug; 11(1):16144. PubMed ID: 34373540
[TBL] [Abstract][Full Text] [Related]
40. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.
Planas D; Veyer D; Baidaliuk A; Staropoli I; Guivel-Benhassine F; Rajah MM; Planchais C; Porrot F; Robillard N; Puech J; Prot M; Gallais F; Gantner P; Velay A; Le Guen J; Kassis-Chikhani N; Edriss D; Belec L; Seve A; Courtellemont L; Péré H; Hocqueloux L; Fafi-Kremer S; Prazuck T; Mouquet H; Bruel T; Simon-Lorière E; Rey FA; Schwartz O
Nature; 2021 Aug; 596(7871):276-280. PubMed ID: 34237773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
